Actelion Statement
(Thomson Reuters ONE) -
Actelion Pharmaceuticals Ltd /
Actelion Statement
Processed and transmitted by Thomson Reuters.
The issuer is solely responsible for the content of this announcement.
ALLSCHWIL/BASEL, SWITZERLAND - 17 November 2010 - Actelion Ltd (SIX: ATLN)
announced today that - as part of its ordinary course of business - the company
is in regular dialogue with other industry participants. No further comment will
be made.
###
Actelion Ltd
Actelion Ltd is a biopharmaceutical company with its corporate headquarters in
Allschwil/Basel, Switzerland. Actelion's first drug Tracleer®, an orally
available dual endothelin receptor antagonist, has been approved as a therapy
for pulmonary arterial hypertension. Actelion markets Tracleer® through its own
subsidiaries in key markets worldwide, including the United States, the European
Union, Japan, Canada, Australia and Switzerland. Actelion, founded in late
1997, is a leading player in innovative science related to the endothelium - the
single layer of cells separating every blood vessel from the blood stream.
Actelion's over 2,400 employees focus on the discovery, development and
marketing of innovative drugs for significant unmet medical needs. Actelion
shares are traded on the SIX Swiss Exchange (ticker symbol: ATLN) as part of the
Swiss blue-chip index SMI (Swiss Market Index SMI®).
[HUG#1463170]
--- End of Message ---
Actelion Pharmaceuticals Ltd
Gewerbestrasse 16 Allschwil Switzerland
ISIN: CH0010532478;
Press Release PDF:
http://hugin.info/131801/R/1463170/402097.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Actelion Pharmaceuticals Ltd via Thomson Reuters ONE
Unternehmensinformation / Kurzprofil:
Datum: 17.11.2010 - 07:00 Uhr
Sprache: Deutsch
News-ID 48837
Anzahl Zeichen: 2449
contact information:
Town:
Allschwil
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 214 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Actelion Statement"
steht unter der journalistisch-redaktionellen Verantwortung von
Actelion Pharmaceuticals Ltd (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
